Mite-impermeable bedding covers,
does it really help with Improved lung function and inhaled-steroid withdrawal in adults with asthma?
research showsThe grade is D with 30 points. In a double-blind randomized trial of 1,122 adults with asthma, the adjusted six-month morning peak-flow difference was -1.6 L/min (95% CI -5.9 to 2.7), P=.46, while complete inhaled-steroid withdrawal during months 7 to 12 was 17.4% versus 17.1%. Zero of the two prespecified primary outcomes was positive.
ads claimBlocking allergen passage and improving adult asthma are different claims. The former was partly demonstrated, while both primary clinical-control outcomes failed.
Useful facts when choosing a product
- The active covers allowed water vapor through while blocking Der p1 and were fitted to mattress, pillow, and duvet.
- At 12 months, mattress Der p1 was 1.05 versus 1.64 micrograms/g, P=.74.
- The covers do not replace inhalers; steroid reduction in the trial followed predefined safety criteria with nurse monitoring.
Chamgap Semantic Classification Code
Candidate index · review held
UNK.house-dust-mite-allergen-impermeable-mattress.UNK.lung-function-and-inhaled-steroid-withdrawal-with-asthma.improve.placeboUnknown > House-dust-mite-allergen-impermeable mattress > Unknown > lung function and inhaled-steroid withdrawal with asthma > Improvement claim > Placebo
An automated migration candidate, not an issued permanent code; exact claim scope remains under review. This machine-generated migration candidate helps retrieval but is not a permanent assignment. The original verdict ID and URL remain authoritative.
What the research actually shows
A coordinating center allocated participants by minimization, and identical-looking non-impermeable covers masked participants and assessors. All 1,122 assigned recipients (560/562) entered analysis, including 732 mite-sensitive participants. Six-month follow-up was completed by 1,015, diaries by 965, and 751 entered steroid reduction. One limitation was retained because the paper did not fully specify primary-analysis handling of missing records and the registry entry followed trial completion, preventing independent confirmation of prospective timing. The UK NHS Research and Development Programme on Asthma Management funded the trial.
Why this is classified as D (30)
Both prespecified primary outcomes were null in one large adult-asthma trial. The peak-flow interval crossed zero, and no validated between-group minimum-benefit boundary was identified to exclude all meaningful benefit, giving D with 30 points.
Counterpoint. Covers can cause sweating or discomfort, and reducing asthma medication without supervision can precipitate worsening.
Rejudgment record. Cross-check applied — Cross-checked the NEJM report and ISRCTN record for both primary outcomes, analysis denominators, coordinating-center allocation, identical control covers, mite-sensitive primary analysis, missing-data reporting, and NHS funding
| Endpoint | S | Surrogate marker - laboratory or imaging measures |
| Replication | R1 | Single confirmatory trial |
| Independence | I2 | Decisive evidence is publicly or non-profit funded |
| Effect size | E0 | Null |
| Precision | C0 | The confidence interval leaves room for benefit |
Stored derived and displayed grades match; this is not a current recalculation or validity check (D).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Improved adult-asthma lung function and medication reduction | D | Neither primary outcome differed between groups. |
| Reduced mattress mite allergen at six months | C | Der p1 was 0.58 versus 1.71 micrograms/g, P=.01. |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Woodcock A, Forster L, Matthews E, Martin J, Letley L, Vickers M, Britton J, Strachan D, Howarth P, Altmann D, Frost C, Custovic A, Medical Research Council General Practice Research Framework. 2003 | Double-blind placebo-controlled randomized trial across 154 general practices | 1,122 randomized recipients (560/562); 732 mite-sensitive; 965 with six-month diaries and 751 entering steroid reduction | Public funding from the UK NHS Research and Development Programme on Asthma Management | Morning peak flow at six months and complete inhaled-steroid withdrawal during months 7 to 12 | -1.6 L/min (95% CI -5.9 to 2.7), P=.46; complete withdrawal 17.4% versus 17.1%. Both primary outcomes were null | Large publicly funded single null trial |
Receipt — 1 References
All 1 cited sources were verified for existence at the original page (as of 2026-08-15).
Final verification and publication gate: Codex · Evidence date: 2026-08-15 · Corrections: none
Cite this verdict
[Chamgap] Mite-impermeable bedding covers x adult asthma control — Evidence Grade D·30. 1 cited sources checked. Source: https://chamgap.com/en/verdicts/immunity/mite-allergen-impermeable-bed-covers-adult-asthma-control/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.